Health care workers
Frontline health care workers are often recommended to get seasonal and any pandemic flu vaccination. For example, in the UK all health care workers involved in patient care are recommended to receive the seasonal flu vaccine, and were also recommended to be vaccinated against the H1N1/09 (later renamed A(H1N1)pdm09) swine flu virus during the 2009 pandemic. However, uptake is often low. During the 2009 pandemic, low uptake by healthcare workers was seen in countries including the UK, Italy, Greece, and Hong Kong.In a 2010 survey of United States health care workers, 63.5% reported that they received the flu vaccine during the 2010–11 season, an increase from 61.9% reported the previous season. US Health professionals with direct patient contact had higher vaccination uptake, such as physicians and dentists (84.2%) and nurse practitioners (82.6%).The main reason to vaccinate health care workers is to prevent staff from spreading flu to their patients and to reduce staff absence at a time of high service demand, but the reasons health care workers state for their decisions to accept or decline vaccination may more often be to do with perceived personal benefits.In Victoria (Australia) public hospitals, rates of health care worker vaccination in 2005 ranged from 34% for non-clinical staff to 42% for laboratory staff. One of the reasons for rejecting vaccines was concern over adverse reactions; in one study, 31% of resident physicians at a teaching hospital incorrectly believed Australian vaccines could cause influenza.
2022 southern hemisphere
The composition of vaccines for use in the 2022 Southern Hemisphere influenza season influenza season recommended by the World Health Organization in September 2021:Egg-based vaccines:

A/Victoria/2570/2019 (H1N1)pdm09-like virus;
A/Darwin/9/2021 (H3N2)-like virus;
B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.Cell- or recombinant-based vaccines:

A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
A/Darwin/6/2021 (H3N2)-like virus;
B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.It is recommended that trivalent influenza vaccines for use in the 2022 southern hemisphere influenza season contain the following:
Egg-based vaccines:

A/Victoria/2570/2019 (H1N1)pdm09-like virus;
A/Darwin/9/2021 (H3N2)-like virus; and
B/Austria/1359417/2021 (B/Victoria lineage)-like virus.Cell- or Recombinant-based vaccines:

A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
A/Darwin/6/2021 (H3N2)-like virus; and
B/Austria/1359417/2021 (B/Victoria lineage)-like virus

2022–2023 northern hemisphere
The composition of virus vaccines for use in the 2022–2023 Northern Hemisphere influenza season is
European UnionThe composition of virus vaccines for use in the European Union for the 2022–2023 Northern Hemisphere influenza season recommended by the European Medicines Agency on March 29, 2022, is:Quadrivalent egg-based or live attenuated vaccines should contain:
an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
an A/Darwin/9/2021 (H3N2)-like virus;
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.Quadrivalent cell-culture or recombinant-based vaccines should contain:
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
an A/Darwin/6/2021 (H3N2)-like virus;
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.United StatesThe FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the quadrivalent formulation of egg-based influenza vaccines for the U.S. 2022-2023 influenza season contain the following:
an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
an A/Darwin/9/2021 (H3N2)-like virus;
a B/Austria/1359417/2021-like virus (B/Victoria lineage); and
a B/Phuket/3073/2013-like virus (B/Yamagata lineage).The committee recommended that the quadrivalent formulation of cell- or recombinant-based influenza vaccines for the US 2022–2023 influenza season contain the following:
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
an A/Darwin/6/2021 (H3N2)-like virus;
a B/Austria/1359417/2021-like virus (B/Victoria lineage); and
a B/Phuket/3073/2013-like virus (B/Yamagata lineage).For trivalent influenza vaccines for use in the US for the 2022–2023 influenza season, depending on the manufacturing method of the vaccine, the committee recommended that the A(H1N1)pdm09, A(H3N2) and B/Austria/1359417/2021-like virus (B/Victoria lineage) viruses recommended above for the quadrivalent vaccines be used.